A549+RFP人肺癌細(xì)胞（紅
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/4/24 14:52:54
- 訪問次數(shù) 75
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息，謝謝!
人肺癌細(xì)胞帶紅色熒光 A549+RFP
| 種屬 | 人 |
| 別稱 | A549+RFP |
| 組織來源 | 肺 |
| 疾病 | 肺腺癌 |
| 傳代比例/細(xì)胞消化 | 1：2-1:3傳代 ，消化3-5分鐘 |
| 培養(yǎng)基配置 | Ham's F-12K培養(yǎng)基；10%胎牛血清；1%雙抗 |
| 簡(jiǎn)介 | 該細(xì)胞系由D.J.Griad通過肺癌組織移植培養(yǎng)建系 ，患者為58歲白人男性。A549能通過胞苷二磷酸途徑合成含有 高含量不飽和脂肪酸的。 |
| 形態(tài) | 上皮細(xì)胞樣 |
| 生長(zhǎng)特征 | 貼壁生長(zhǎng) |
| 倍增時(shí)間 | ~22h |
| STR | Amelogenin：X ，Y；CSF1PO：10 ，12；D13S317：11；D16S539：11 ，12；D18S51：14 ，17； D19S433：13；D21S11：29；D2S1338：24；D3S1358：16；D5S818：11；D7S820：8 ，11；D8S1179： 13 ，14；FGA：23；TH01：8 ，9.3；TPOX：8 ，11；vWA：14； |
| 培養(yǎng)條件 | 氣相 ：空氣 ，95% ；二氧化碳 ，5%。 溫度 ：37攝氏度 ，培養(yǎng)箱濕度為70%-80%。 |
| 凍存條件 | 凍存液 ：90%FBS ，DMSO 10%, 或使用非程序凍存液 ：貨號(hào)JY-H040 |
| 備注 | 該細(xì)胞是通過慢病毒轉(zhuǎn)染熒光素酶的穩(wěn)轉(zhuǎn)株 ，收到細(xì)胞傳代8代左右后 ，若要求需要維持熒光強(qiáng)度 ，建議可以加入嘌呤 霉素進(jìn)行再次篩選。 |
| 產(chǎn)品使用 | 于科學(xué)研究 ，不可作為動(dòng)物或人類疾病的治療產(chǎn)品使用。 |
pathways[J]. Mol Cell Biochem, 2017, 428(1-2):41-56.
[ ARRIETA-CRUZ I, SU Ya, KNIGHT C M, et al.
Evidence for a role of proline and hypothalamic
astrocytes in the regulation of glucose metabolism
in rats[J]. Diabetes, 2013, 62(4):1152-8.
infiltration was reduced , cells were more neatly ar- ranged and fibrous hyperplasia improved; compared with the NC group , the HC group showed significantly higher Ishak score , Ishak stage , liver index , Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for patients with non-homologous recombination deficient (HRD) disease. Folate receptor alpha (FOLR1/FRα)-targeting agents have shown promise both alone and in combination with available therapies, but the relationship of FRα to other treatment-driving biomarkers is unknown. The Cancer Genome Atlas (TCGA) was queried to assess protein and mRNA expression and mutational burden in patients with differential FRα protein-expressing ovarian tumors, and the results referenced against the standard 324 mutations currently tested through FoundationOne Companion Diagnostics to identify targets of interest. Of 585 samples within TCGA, 121 patients with serous ovarian tumors for whom FRα protein expression was quantified were identified. FRα protein expression significantly correlated with FOLR1 mRNA expression (p=7.19×10 - 14 ). Progression free survival (PFS) for the FRα-high group (Q1) was 20.7 months, compared to 16.6 months for the FRα-low group (Q4, Logrank, p=0.886). Overall survival (OS) was 54.1 months versus 36.3 months, respectively; however, this result was not significant (Q1 vs. Q4, Logrank, p=0.200). Mutations more commonly encountered in patients with high FRα-expressing tumors included PIK3CA and FGF family proteins. Combinations of FRα-targeting agents with PI3K, mTOR, FGF(R) and VEGF inhibitors warrant investigation to evaluate their therapeutic potential.
采購(gòu)中心
化工儀器網(wǎng)